Kristen Zhang

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

A. Becker, J. Powers, A. Udyavar, 2022, Molecular cancer therapeutics.

Abstract 4561: Preclinical characterization of GLS-010 (AB122): A fully humanized clinical-stage anti-PD-1 antibody

Yong Zheng, Xiaoning Zhao, Kai Chen, 2018, Clinical Research (Excluding Clinical Trials).

Abstract 1756: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy

U. Schindler, Lixia Jin, Ada Chen, 2018, Immunology.

Abstract 710: CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors (ICI)

A. Becker, U. Schindler, J. Powers, 2018, Immunology.

AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors

A. Becker, U. Schindler, J. Powers, 2018 .